Sumitomo Pharma Co.

4506.TSE

11.05 USD

-0.48

-4.16%

Overview

Last close

11.05 usd

Market cap

4.39B usd

52 week high

12.23 usd

52 week low

1.81 usd

Target price

10.82 usd

Valuation

P/E

27.7329

Forward P/E

20.202

Price/Sales

1.5742

Price/Book Value

3.8189

Enterprise Value

6.46B usd

EV/Revenue

2.3717

EV/EBITDA

16.6909

Key financials

Revenue TTM

2.84B usd

Gross Profit TTM

1.73B usd

EBITDA TTM

416.78M usd

Earnings per Share

0.41 usd

Dividend

N/A usd

Total assets

5.09B usd

Net debt

2.00B usd

About

Sumitomo Pharma Co., Ltd. engages in manufacture, purchase, and sale of pharmaceutical products for medical treatment in Japan, North America, and Asia. The company offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. It also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, the company offers veterinary drugs, medical devices, etc. It has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.